Literature DB >> 24846123

c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.

Rosa Molfetta1, Linda Quatrini, Cristina Capuano, Francesca Gasparrini, Beatrice Zitti, Alessandra Zingoni, Ricciarda Galandrini, Angela Santoni, Rossella Paolini.   

Abstract

The NKG2D activating receptor on human NK cells mediates "altered self" recognition, as its ligands (NKG2DLs) are upregulated on target cells in a variety of stress conditions. Evidence collected in the past years shows that, even though expression of NKG2DLs acts as a danger signal that renders tumor cells susceptible to cytotoxicity, chronic exposure to soluble or membrane-bound NKG2DLs can lead to down-modulation of receptor expression and impairment of NKG2D-mediated cell functions. Here, we evaluated whether different cell-bound NKG2DLs, namely MICA and ULBP2, are equivalently able to induce NKG2D down-modulation on human NK cells. We found that although both ligands reduce NKG2D surface expression, MICA promotes a stronger receptor down-modulation than ULBP2, leading to a severe impairment of NKG2D-dependent NK-cell cytotoxicity. We also provide evidence that the ubiquitin pathway and c-Cbl direct MICA-induced but not ULBP2-induced NKG2D internalization and degradation, thus identifying a molecular mechanism to explain the differential effects of MICA and ULBP2 on NKG2D expression. A better understanding of the molecular mechanisms employed by the different NKG2DLs to control NKG2D surface expression could be useful for the development of anti-tumor strategies to restore a normal level of NKG2D receptors on human NK cells.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Endocytosis; NK cells; NKG2D ligands; NKG2D receptor

Mesh:

Substances:

Year:  2014        PMID: 24846123     DOI: 10.1002/eji.201444512

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  14 in total

1.  Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation.

Authors:  Cinzia Fionda; Helena Stabile; Rosa Molfetta; Andrea Kosta; Giovanna Peruzzi; Silvia Ruggeri; Alessandra Zingoni; Cristina Capuano; Alessandra Soriani; Rossella Paolini; Angela Gismondi; Marco Cippitelli; Angela Santoni
Journal:  Eur J Immunol       Date:  2021-09-18       Impact factor: 6.688

Review 2.  E3 ubiquitin ligase Casitas B lineage lymphoma-b and its potential therapeutic implications for immunotherapy.

Authors:  D Jafari; M J Mousavi; S Keshavarz Shahbaz; L Jafarzadeh; S Tahmasebi; J Spoor; A Esmaeilzadeh
Journal:  Clin Exp Immunol       Date:  2021-01-10       Impact factor: 5.732

Review 3.  Modulation of Immune Cell Functions by the E3 Ligase Cbl-b.

Authors:  Christina Lutz-Nicoladoni; Dominik Wolf; Sieghart Sopper
Journal:  Front Oncol       Date:  2015-03-11       Impact factor: 6.244

4.  Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells.

Authors:  Beatrice Zitti; Rosa Molfetta; Cinzia Fionda; Linda Quatrini; Helena Stabile; Mario Lecce; Valeria de Turris; Maria Rosaria Ricciardi; Maria Teresa Petrucci; Marco Cippitelli; Angela Gismondi; Angela Santoni; Rossella Paolini
Journal:  Sci Rep       Date:  2017-09-05       Impact factor: 4.379

5.  Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production.

Authors:  Cristina Capuano; Chiara Pighi; Rosa Molfetta; Rossella Paolini; Simone Battella; Gabriella Palmieri; Giuseppe Giannini; Francesca Belardinilli; Angela Santoni; Ricciarda Galandrini
Journal:  Oncoimmunology       Date:  2017-02-10       Impact factor: 8.110

6.  Antigen Loss Variants: Catching Hold of Escaping Foes.

Authors:  Maulik Vyas; Rolf Müller; Elke Pogge von Strandmann
Journal:  Front Immunol       Date:  2017-02-24       Impact factor: 7.561

Review 7.  NKG2D and Its Ligands: "One for All, All for One".

Authors:  Alessandra Zingoni; Rosa Molfetta; Cinzia Fionda; Alessandra Soriani; Rossella Paolini; Marco Cippitelli; Cristina Cerboni; Angela Santoni
Journal:  Front Immunol       Date:  2018-03-12       Impact factor: 7.561

8.  A nanoscale reorganization of the IL-15 receptor is triggered by NKG2D in a ligand-dependent manner.

Authors:  Štefan Bálint; Filipa B Lopes; Daniel M Davis
Journal:  Sci Signal       Date:  2018-04-10       Impact factor: 8.192

Review 9.  The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.

Authors:  Tobias Bald; Matthew F Krummel; Mark J Smyth; Kevin C Barry
Journal:  Nat Immunol       Date:  2020-07-20       Impact factor: 25.606

Review 10.  Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis.

Authors:  Rosa Molfetta; Linda Quatrini; Angela Santoni; Rossella Paolini
Journal:  Int J Mol Sci       Date:  2017-08-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.